Endocrinology Vol. 142, No. 1 414-420
Copyright © 2001 by The Endocrine Society
Restoration of Growth Hormone-Releasing Hormone (GHRH) Responsiveness in Pituitary GH3 Cells by Adenovirus-Directed Expression of the Human GHRH Receptor1
Eun Jig Lee,
W. Rachel Duan,
Tom Kotlar and
J. Larry Jameson
Division of Endocrinology, Metabolism, and Molecular Medicine,
Northwestern University Medical School, Chicago, Illinois 60611
Address all correspondence and requests for reprints to: J. Larry Jameson, M.D., Ph.D., Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Medical School, 303 East Chicago Avenue, Chicago, Illinois 60611. E-mail:
ljameson{at}northwestern.edu
 |
Abstract
|
|---|
GH-secreting GH3 cells lack GH-releasing hormone (GHRH) receptors. In
this study we used adenoviral vectors to transfer the human GHRH
receptor to GH3 cells in an effort to restore GHRH responsiveness. A
replication-deficient recombinant adenovirus (AdGHRH-R) was designed to
allow cytomegalovirus promoter-driven expression of the GHRH receptor
messenger RNA. COS-7 cells and GH-producing GH3 cells infected with
AdGHRH-R showed GHRH receptor expression on their membranes and
exhibited specific GHRH binding. The addition of GHRH to GH3 cells
infected with AdGHRH-R increased cAMP levels, induced cAMP response
element-binding protein phosphorylation and restored GH secretory
responsiveness. GHRH treatment also caused activation of
mitogen-activated-protein kinase, induction of c-fos,
stimulation of GH promotor activity, and increased cellular
proliferation. These findings indicate that adenoviral vectors carrying
human GHRH receptor are useful for in vitro studies of
GHRH receptor biology and represent a first step toward the development
of gene therapy for dwarfism caused by GHRH receptor mutations.
 |
Introduction
|
|---|
THE HYPOTHALAMIC peptide, GH-releasing
hormone (GHRH) plays a critical role in somatotrope proliferation and
GH synthesis and secretion. The GHRH receptor, a G protein-coupled cell
membrane receptor, mediates GHRH action on pituitary somatotrope cells.
The GHRH receptor is coupled to Gs
, resulting
in the activation of adenylate cyclase; cAMP can mimic most of the
effects of GHRH, including stimulation of GH synthesis and secretion
and proliferation of somatotrope cells in the pituitary
(1, 2, 3, 4). Inhibition of downstream effects of cAMP leads to
somatotrope depletion and dwarfism in transgenic mice (5).
A recent study revealed that inactivating mutations of the GHRH
receptor gene cause somatotrope hypoplasia and profound dwarfism in the
little mouse (lit/lit) (6). This
mutant receptor fails to bind GHRH (7), precluding
subsequent signaling by the peptide. Mutations in the human (h) GHRH
receptor have recently been identified in families with dwarfism
(8, 9, 10). These mutations generate a severely truncated
receptor or impair receptor processing, leading to hypoplasia of
pituitary somatotropes. Genetic treatment of such patients is
theoretically possible by transfer and expression of a wild-type GHRH
receptor.
GH3 cells, a rat pituitary GH- and PRL-producing cell line, have
been valuable for studies of hormonal secretory physiology
(11) and signal transduction pathways. However, GHRH fails
to stimulate GH secretion or GH messenger RNA production in GH3
cells (12), suggesting the absence of GHRH receptors in
this cell line. Replication-deficient, recombinant adenovirus vectors
represent a highly efficient means for transferring genes in
vitro and in vivo and are being used in a wide variety
of applications in cell culture, experimental animals, and human gene
therapy. We tested the feasibility of GHRH receptor gene transfer using
a recombinant adenovirus and analyzed the functional effects of GHRH
receptor transfer to GH3 cells, including the effects on signal
transduction and cell proliferation.
 |
Materials and Methods
|
|---|
Generation of recombinant adenoviral vectors
The recombinant adenoviral vectors were generated using
adenovirus type 5 (Ad5 309/356), in which the E3 region has been
deleted. A cassette containing the hGHRH receptor complementary DNA
(provided by Kelly E. Mayo, Northwestern University, Chicago, IL),
driven by the cytomegalovirus (CMV) promoter/enhancer (654 bp) with a
simian virus 40 polyadenylation sequence, was inserted in place of the
E1 deletion. Four different recombinant adenoviral vectors were
generated as described previously (13): AdGHRH-R,
AdAS, AdGHGal, and AdCMVGal (Fig. 1
).
AdAS, containing the antisense GHRH receptor, was used as a negative
control. AdGHGal, which contains ß-galactosidase driven by the hGH
promoter (-610, +58), was used as a reporter. AdCMVGal
(13) was used to determine the efficiency of gene
transduction. Individual clones of the recombinant adenoviral vectors
were purified and titrated by plaque assays. The sequences of the
expression cassettes in the adenoviral vectors were confirmed by
automated DNA sequencing of viral DNA using specific primers.

View larger version (30K):
[in this window]
[in a new window]
|
Figure 1. Structures of recombinant adenoviruses. The
adenoviral vector contains a backbone derived from adenovirus type 5
(Ad5 309/356), in which the E3 regions have been deleted. The genes of
interest (shaded area) were inserted in the E1 region.
Four different recombinant adenoviral vectors were generated: AdGHRH-R,
AdAS, AdGHGal, and AdCMVGal. AdAS, containing antisense GHRH receptor
complementary DNA, was used as a negative control. AdGHGal, which
contains the ß-galactosidase gene driven by the hGH promoter (-610
to +58), was used as a reporter. AdCMVGal was used to determine the
efficiency of gene transduction. The CMV promoter contains 654 bp of
the immediate-early enhancer region of the CMV gene.
|
|
Cells cultures and infection with recombinant adenoviruses
GH and PRL producing GH3 cells, COS-7 cells, and HEK293
embryonic kidney cell lines were obtained from the American Type Culture Collection (Manassas, VA). HEK293 cells and COS-7 cells
were maintained in DMEM supplemented with 10% FBS. GH3 cells were
grown in DMEM/Hams F-12 containing 10% FBS. All media were
supplemented with 100 U/ml penicillin and 100 µg/ml streptomycin and
maintained at 37 C with 5% CO2.
Twenty-four-hour after plating cells, infections were carried out by
the addition of viral solutions to cell monolayers and incubation at 37
C for 1 h with brief agitation every 15 min. After the addition of
new culture medium, infected cells were returned to the 37 C incubator,
and medium was changed 24 h later. Transduction efficiency of
adenoviral vectors was tested in cell lines using AdCMVGal.
ß-Galactosidase gene expression was detected in 95100% of GH3
and COS-7 cells at 48 h after infection [5 plaque-forming units
(PFU)/cell; data not shown]. Subsequent experiments were performed
using the same concentration of the other recombinant adenoviral
vectors.
For measurement of cAMP and pituitary hormones and for ligand binding
studies, cells were plated in 12-well culture plates at a density of
2 x 105 cells/well. Triplicate wells were
infected with adenoviral vectors at 5 PFU/cell. For Western blot
analysis, cells were plated in 10-cm culture plates at a density of
5 x 106 cells/well. Cells were analyzed
48 h after infection of adenoviral vectors.
Immunofluorescence of GHRH receptor
Cells were plated on fibronectin-coated chamber slides
(Becton Dickinson and Co., Bedford, MA) and infected with
each virus at 5 PFU/cell. Forty-eight hours after infection, cells were
washed with PBS twice and fixed with 4% paraformaldehyde in PBS (pH
7.4) for 5 min. The slides were incubated with rabbit anti-hGHRH
receptor (1:1000; provided by Dr. Bruce Gaylinn, University of
Virginia, Charlottesville, VA) at room temperature for 1 h. After
washing with Tris-buffered saline/0.025% Tween, staining was performed
using biotinylated secondary antibodies (ABC kit, Vector Laboratories, Inc., Burlingame, CA), and
streptavidin-fluorescein isothiocyanate (1:100; Vector Laboratories, Inc.). The photomicrographs were taken using a
Carl Zeiss microscope (Axioskop, Carl Zeiss,
Oberkochen, Germany) and Fuji Photo Film Co., Ltd. color
film (1600 Super HG, Fuji Photo Film Co., Ltd., Tokyo,
Japan).
Measurement of ligand binding
GH3 or COS-7 cells infected with adenoviral vectors were
rinsed with 1.0 ml binding buffer: 50 mM HEPES, 100
mM sucrose, 5 mM
CaCl2·6H2O, 0.1%
(wt/vol) ovalbumin. 125I-labeled (50,000 dpm)
hGHRH-(144) amide (Amersham Pharmacia Biotech,
Piscataway, NJ) was added to each well with various amounts of
unlabeled hGHRH-(144) amide (Sigma, St. Louis,
MO) in binding buffer at the indicated concentration. Incubation was
continued at room temperature for 3 h, and cells were rinsed twice
with 1.0 ml binding buffer followed by the addition of 0.5 ml 1.0
N NaOH. After 1 h, the wells were scraped, and the
contents were transferred to a glass tube and washed twice with 0.25 ml
1.0 N NaOH. 125I radioactivity was
measured in a
-counter (United Technologies Packard, Downers Grove,
IL), and binding curves were determined using Prism analysis software
(GraphPad Software, Inc., San Diego, CA).
Measurement of intracellular cAMP levels
GH3 and COS-7 cells infected with adenoviral vectors were
treated with 0.1 mM isobutylmethylxanthine for 20 min at 37
C. The hGHRH (144) amide was added in fresh warmed medium, and
incubation was continued for 30 min at 37 C. The medium was removed,
and 0.5 ml cold 0.1 M HCl was added to each well and
harvested. Cell lysates were centrifuged for 10 min at 4 C to remove
protein, and the supernatants were neutralized with an equal volume of
150 mM Tris-HCl (pH 8.6) containing 4 mM EDTA.
The cAMP levels were measured using a RIA kit (Biomedical Technologies, Stoughton, MA) according to the manufacturers
instructions.
Measurement of inositol phosphate accumulation
Twenty-four hours after infection, triplicate wells of cells
were labeled with tritiated myo-inositol (NEM Life Science Products,
Inc., Boston, MA) for 24 h. The medium was replaced by
Krebs-Ringer-bicarbonate buffer (pH 7.4) containing 20 mM
lithium chloride and hGHRH-(144) amide (10 nM) and
incubated for 1 h at 37 C. Ice-cold methanol (0.75 ml) was added
to each well, and cells were scraped into a tube containing 0.66 ml
chloroform and diluted by the addition of 0.75 ml water. The tubes were
sonicated for 10 sec and centrifuged at 10,000 rpm at 4 C. The
tritiated inositol phosphates (IP) in the aqueous layer were isolated
by ion exchange chromatography. The organic phase (0.2 ml), containing
nonhydrolyzed phosphatidyl inositol (PI), was evaporated in a
scintillation vial. Tritium was measured in a liquid scintillation
counter (Beckman Coulter, Inc., Fullerton, CA). Inositol
phosphate accumulation is expressed as a percentage tritiated IP
divided by the sum of tritiated IP and PI.
Measurement of GH and PRL in cell culture medium
GH3 cells infected with adenoviral vectors were washed
twice with prewarmed DMEM/Hams F-12 without serum, and the same
medium containing hGHRH-(144) amide (1 nM) was added.
Aliquots were collected at 5, 15, 30, and 60 min after the addition of
ligand. The samples were frozen at -20 C until assayed for GH and PRL.
The levels of GH and PRL were measured with a RIA kit provided by the
National Hormone and Pituitary Program (NIDDK, NIH).
Western blot analysis
GH3 cells and COS-7 cells were grown in a 10-cm plate and
infected with adenoviral vectors at 5 PFU/cell. Forty-eight hours after
infection, cells were treated with hGHRH-(144) amide (1
nM) for various time intervals. Cells were washed with
ice-cold PBS and harvested with 5 ml PBS+ (PBS, 1
mM EDTA, 1 mM phenylmethysulfonylfluoride and 1
mM dithiothreitol). Nuclear extracts were prepared by the
Shapiro method (14) modified by the addition of protease
inhibitor cocktail tablets, Complete (Roche Molecular Biochemicals, Indianapolis, IN), and 25 mM NaF. In
the experiments that involved GHRH receptor and
mitogen-activated protein kinase (MAPK), whole cell lysis was prepared
with lysis buffer [25% glycerol, 0.5 M NaCl, 1.5
mM MgCl2, 20 mM HEPES (pH
7.9), 1 mM phenylmethysulfonylfluoride, 0.2 mM
EDTA, 25 mM NaF, and protease inhibitor cocktail tablets,
Complete]. Proteins were solubilized in 1% Nonidet P-40. Equal
amounts of proteins were resolved by 10% SDS-PAGE and transferred onto
nitrocellulose filters. The membranes were blocked with 3% nonfat milk
in PBS for 1.5 h and then incubated overnight at 4 C with rabbit
polyclonal antibodies against either total cAMP response
element-binding protein (CREB) or
Ser133-phosphorylated CREB (Upstate Biotechnology, Inc., Lake Placid, NY). To detect Pit-1, c-Fos,
MAPK, or GHRH receptor, membranes were incubated with rabbit anti-Pit-1
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA), rabbit
anti-c-Fos (Santa Cruz Biotechnology, Inc.), rabbit
anti-phospho-p44/p42 MAPK (New England Biolabs, Inc.,
Beverly, MA), or rabbit anti-hGHRH receptor antibody (provided by Dr.
Bruce Gaylinn). Immunoreactive proteins were detected using an
antirabbit horseradish peroxidase-conjugated antibody (1:5000) and the
enhanced chemiluminescence system (Amersham Pharmacia Biotech, Arlington Heights, IL). Bands were detected with
Kodak (Rochester, NY) X-Omat film and quantitated using a
GS-700 Imaging Densitometer (Bio-Rad Laboratories, Inc.,
Hercules, CA).
GH promoter activation by GHRH in AdGHRH-R-infected GH3 cells
AdGHGal, an adenoviral vector containing the ß-galactosidase
gene driven by 0.67 kb of the hGH promoter, was used as a reporter to
evaluate the GHRH activation of GH promoter. Twenty-four hours after
coinfection (5 PFU/cell of each virus) of AdGHGal with AdGHRH-R or
AdAS, hGHRH-(144) amide was added, and the cells were incubated
overnight. Culture medium was aspirated, and cell lysis solution was
added. Triplicate wells of infected cells were used to measure
ß-galactosidase activity using O-nitrophenyl
ß-D-galactopyranoside as a substrate
(Sigma, St. Louis, MO). Cell lysates were mixed with the
O-nitrophenyl ß-D-galactopyranoside
substrate solution and incubated in 37 C for 1 h. The reaction was
stopped with 100 µl 1 M
Na2CO3. Absorption was
measured at 405 nm, and ß-galactosidase activity was calculated using
a standard curve.
Cell proliferation assays of GH3 cells infected with AdGHRH-R
Cell proliferation was measured using a nonradioactive cell
proliferation assay according to the manufacturers protocol
(Cell-Titer 96 Aqueous NonRadioactive Cell Proliferation Assay,
Promega Corp., Madison, WI). GH3 cell cultures were
depleted of estrogen for 4 days using phenol red-free DMEM/Hams F-12
containing 10% dextran/charcoal-stripped FBS. One day after plating
1 x 104 cells in quadruplicate wells of
96-well plates, adenoviral vectors were infected at 5 PFU/cell. Fresh
medium containing 1 nM hGHRH-(144) amide was added every
day for 4 days, at which time cell proliferation was measured. The
growth of GH3 cells was expressed relative to the growth
(mean ± SD) of cells infected with AdGHRH-R without
addition of GHRH.
 |
Results
|
|---|
GHRH receptor expression and functional characterization
GH3 and COS-7 cells were infected with adenoviral
vectors carrying the GHRH receptor (5 PFU/cell) to investigate the
efficacy of GHRH receptor expression. Immunofluorescence was performed
using an anti-hGHRH receptor antibody to assess GHRH receptor
expression in cell membranes. GHRH receptor expression was readily
detected in the membranes of COS-7 and GH3 cells infected with
AdGHRH-R, but not in cells infected with the antisense construct
(AdAS). Expression of GHRH receptor was seen in 95100% of GH3
and COS-7 cells infected with 5 PFU/cell AdGHRH-R (Fig. 2A
).

View larger version (50K):
[in this window]
[in a new window]
|
Figure 2. Expression of the hGHRH receptor in COS-7 and GH3
cells infected with AdGHRH-R. A, Immunofluorescent localization of the
GHRH receptor. Indirect immunofluorescence of GH3 (AC) and COS-7
cells (DF) infected with AdGHRH-R (B, C, E, and F) or AdAS (A and C)
was performed using rabbit anti-hGHRHR receptor. The pictures were
taken using a Carl Zeiss (model) microscope and Fuji Photo Film Co., Ltd. 1600 film. B, Western blot analysis of the
GHRH receptor. Membrane extracts of GH3 (lanes 1 and 2) and COS-7 cells
(lanes 3 and 4) infected with AdAS (lanes 1 and 3) or AdGHRH-R (lanes 2
and 4) were analyzed using the same antibody.
|
|
Western blot analysis was also performed to assess GHRH receptor
expression (Fig. 2B
). A GHRH receptor-specific band of approximately 52
kDa was detected in GH3 and COS-7 cells infected with AdGHRH-R.
This band was not observed in cells infected with AdAS.
AdGHRH-R-infected GH3 cells also showed a higher molecular mass
band, presumably corresponding to different form of glycosylated GHRH
receptor.
GHRH binding to receptors was analyzed in cells infected with
adenoviral vectors (Fig. 3
). GHRH
bound to AdGHRH-R-infected GH3 cells with a
Kd of 3.46 nM. The number of
expressed receptors expressed ranged from 186,000277,000/cell. No
GHRH binding was detected in cells infected with AdAS. COS-7 cells
infected with AdAS exhibited a low amount of specific GHRH binding,
suggesting that these cells may have a small number of endogenous
GHRH-binding sites.

View larger version (19K):
[in this window]
[in a new window]
|
Figure 3. Binding of GHRH to GHRH receptors in GH3 or COS-7
cells infected with AdGHRH-R or AdAS. 125I-Labeled and
increasing concentrations of unlabeled hGHRH-(144) amide were added
to plated cells. Results are expressed as a percentage of the maximum
specific binding.
|
|
cAMP levels were measured to determine whether the expression of GHRH
receptors by adenoviral vectors mediates signal transduction in
response to GHRH. An increase in intracellular cAMP was detected at
10-11 M GHRH
and reached maximal values at
10-9 M GHRH in
GH3 and COS-7 cells infected with AdGHRH-R (Fig. 4A
). GH3 cells infected with AdAS
showed no cAMP increase in response to GHRH, whereas AdAS-infected
COS-7 cells showed a slight increase (24.5 ± 0.9
pM/well) in cAMP at high concentrations of GHRH
(10-7 M).

View larger version (22K):
[in this window]
[in a new window]
|
Figure 4. GHRH-stimulated cAMP accumulation in GH3 or COS-7
cells infected with AdGHRH-R or AdAS. A, Intracellular cAMP
accumulation in response to different doses of GHRH. The
EC50 value is 30 pM. B, The maximal cAMP
response at 10-9 M GHRH was tested
using increasing doses of adenoviral vectors.
|
|
The cAMP response to GHRH plateaued at 5 PFU/cell AdGHRH-R in GH3
cells and 10 PFU/cell in COS-7 cells (Fig. 4B
). This suggests that the
cellular capacity to generate cAMP may be saturated by these high
levels of GHRH receptor expression.
To investigate the possibility of involvement of protein kinase C (PKC)
pathway in GHRH receptor signal transduction, inositol phosphate
accumulation was measured in cells expressing the GHRH receptor. TRH
was used as a positive control because the endogenous TRH receptor in
GH3 cells is linked to the PKC pathway. GHRH did not stimulate
inositol phosphate accumulation in GH3 or COS-7 cells infected
with AdGHRH-R (Fig. 5
). In contrast, TRH
stimulated high levels of inositol phosphate accumulation in GH3
cells. This suggests that GHRH does not activate the PKC pathway in
somatotrope cells.

View larger version (21K):
[in this window]
[in a new window]
|
Figure 5. Inositol phosphate (IP) accumulation in GH3 or
COS-7 cells infected with AdGHRH-R or AdAS. IP accumulation in GH3
cells stimulated by TRH was measured as a positive control.
|
|
GH and PRL secretion of GH3 cells by GHRH
To evaluate whether GHRH receptor expressed by adenoviral vector
reconstitutes GH or PRL secretion, GHRH was added to GH3 cells
infected with AdGHRH-R. The secretion of GH and PRL increased
significantly at 15, 30, and 60 min after GHRH addition in
AdGHRH-R-infected GH3 cells. AdAS-infected GH3 cells showed
no GH or PRL secretory response to GHRH stimulation (Fig. 6
, A and B).

View larger version (10K):
[in this window]
[in a new window]
|
Figure 6. GH and PRL responses to GHRH in GH3 cells infected
with AdGHRH-R or AdAS. GH (A) and PRL (B) levels in culture media were
measured 5, 15, 30, and 60 min after adding GHRH (1 nM).
The data were expressed as the mean ± SD of
triplicate samples.
|
|
CREB phosphorylation in AdGHRHR-infected GH3 and COS-7 cells
GH3 and COS-7 cells were infected with AdGHRH-R or AdAS and
treated with GHRH to determine whether it alters CREB phosphorylation.
GHRH increased the level of pCREB more than 10-fold within 5 min in
GH3 cells and 2- to 3-fold in COS-7. This level of phosphorylation
was sustained for at least 1 h (Fig. 7
). There was no significant change in
the pCREB level in cells infected with AdAS. The total amount of CREB
was unchanged throughout this time course (Fig. 7
).

View larger version (24K):
[in this window]
[in a new window]
|
Figure 7. CREB phosphorylation in COS-7 (A) or GH3 (B) cells
infected with AdGHRH-R or AdAS. Western blot analysis was performed
using rabbit polyclonal antibodies against either total CREB or
Ser133-phosphorylated CREB.
|
|
Pit-1 expression, MAPK activation, and c-Fos induction in GH3
cells
Levels of Pit-1, MAPK, and c-Fos, all potential targets of GHRH
receptor, were also measured. As shown in Fig. 8A
, Pit-1 was abundantly expressed in the
absence of GHRH in both GH3 cell groups infected with AdAS or
AdGHRH-R. GHRH did not alter Pit-1 expression. In contrast, GHRH
induced MAPK activation within 5 min and dramatically increased the
level of c-Fos by 2 h in GH3 cells infected with AdGHRH-R
(Fig. 8C
).

View larger version (51K):
[in this window]
[in a new window]
|
Figure 8. Pit-1 expression, MAP kinase activation, and c-Fos
induction in GH3 cells infected with AdGHRH-R. Western blot analysis
was performed using rabbit anti-Pit-1, rabbit anti-c-Fos, or rabbit
anti-phospho-p44/p42 MAPK.
|
|
GH promoter activation in GH3 cells by GHRH
AdGHGal, an adenoviral vector containing the ß-galactosidase
gene driven by 0.67 kb of the hGH promoter, was used as a reporter to
evaluate the ability of AdGHRH-R to activate the GH promoter. Basal
ß-galactosidase activity of AdGHGal was greater in GH3 cells
than in COS-7 cells. GHRH induced a 2- to 3-fold increase in
ß-galactosidase activity in GH3 cells infected with AdGHRH-R.
GHRH did not increase ß-galactosidase activity in GH3 cells
infected with AdAS. In COS-7 cells infected with AdGHRH-R there was no
increase in the ß-galactosidase activity in response to GHRH (Fig. 9
), presumably because these cells lack
the specific transcription factors required for GH promoter
function.

View larger version (22K):
[in this window]
[in a new window]
|
Figure 9. GH promoter activation in GH3 or COS-7 cells
infected with AdGHRH-R. AdGHGal, an adenoviral vector containing the
ß-galactosidase gene driven by 0.67 kb of hGH promoter, was used as a
reporter to evaluate the activation of the GH promoter. Twenty-four
hours after infection of cells with adenoviral vectors (5 PFU/cell),
hGHRH was added overnight. Triplicate cell lysates were used to measure
ß-galactosidase activity.
|
|
Effect on cellular proliferation of GH3 cells
Cell proliferation of GH3 cells expressing the GHRH receptor
was examined after GHRH addition. Estrogen- depleted medium was
used to avoid a possible proliferative effect of estrogen in these
estrogen-transformed cells. GHRH (1 nM) significantly
stimulated the proliferation of AdGHRH-R-infected GH3 cells (Fig. 10
).

View larger version (15K):
[in this window]
[in a new window]
|
Figure 10. Effect of GHRH administration on growth of GH3
cells infected with AdGHRH-R. Cell proliferation was measured with a
nonradioactive cell proliferation assay. GH3 cells were depleted of
estrogen for 4 days. Cells (1 x 104) in quadruplicate
wells of 96-well plates were infected with adenoviral vectors at 5
PFU/cell. Fresh medium (dextran/charcoal-stripped FBS) containing 1
nM hGHRH was added every day, and cell proliferation was
assayed on day 4 after the first GHRH dose.
|
|
 |
Discussion
|
|---|
Adenovirus is an attractive vehicle for gene transfer and
transgene expression in mammalian cells because high efficiency gene
transduction can be achieved in a wide variety of quiescent and
proliferating cells (15, 16). Using a recombinant
adenoviral system, a functional hGHRH receptor was expressed in COS-7
cells and GH3 cells. Infection with the AdGHRH-R resulted in a
high level of GHRH receptor expression, specific GHRH binding, cAMP
responsiveness, and CREB phosphorylation after stimulation by GHRH. We
also demonstrated the restoration of GHRH responsiveness in GH3
cells infected with AdGHRH-R, as demonstrated by GH gene stimulation,
increased GH secretion and cellular proliferation.
The GHRH receptor is an N-linked glycoprotein, and
photoaffinity cross-linking studies have revealed three distinct
receptor glycosylation forms, two complex and one core-glycosylated
(high mannose) form (7, 17). In Western blot analyses, two
GHRH receptor bands were seen in GH3 cells, whereas only one band
was detected in COS-7 cells, suggesting that different forms of
glycosylation may occur in various cell types.
It is notable that COS-7 cells, which are derived from kidney, exhibit
low levels of GHRH binding and respond to high doses of GHRH. Mayo
et al. (5) reported GHRH receptor messenger RNA
expression in rat kidney using a RT-PCR assay. The biological role of
the GHRH receptor in kidney, if any, is unknown.
The efficiency of infection combined with the strong activity of the
CMV promoter presumably resulted in supraphysiological receptor
expression in excess of available G protein. These conditions
may result in uncoupled, low affinity receptors, as suggested by the
relatively high Kd for GHRH. In contrast, cAMP
production, which requires the coupled receptor, showed the expected
higher affinity EC50.
An established function of the GHRH receptor in pituitary somatotrope
cells is to mediate the release of GH in response to GHRH. Increased
cAMP levels mediate the phosphorylation of ion channels, leading to the
opening of a Na+-permeable ion channel,
depolarization of the cell membrane, and influx of
Ca2+ through the L-type
Ca2+ channels. The increase in intracellular
Ca2+ levels promotes GH release through the
process of exocytosis (18). We have shown that
adenovirus-mediated expression of GHRH receptor in GH3 cells
confers GH secretion in response to GHRH. The ability to reconstitute
the GHRH receptor signaling system using the adenovirus system will
allow further investigation of GH secretory pathways.
GHRH stimulates transcription of the GH gene in pituitary somatotrope
cells (19, 20). Stimulation of the cAMP pathway and
activation of protein kinase A lead to phosphorylation and activation
of the transcription factor CREB. It has been suggested that CREB
induced synthesis of Pit-1 or perhaps other action of phospho-CREB lead
to a subsequent increase in GH gene expression. In this study, we
observed rapid CREB phosphorylation and GH gene stimulation after the
addition of GHRH to GH3 cells expressing the GHRH receptor. However,
the amount of Pit-1 protein did not increase significantly during the
time of GHRH treatment. In agreement with previous studies (21, 22), basal expression of Pit-1 (in the absence of GHRH
stimulation) is relatively high in these cells. These observations may
explain the high basal activity of the GH promoter in GH3 cells,
but the basis for further activation of the GH promoter by GHRH remains
to be determined. Possible explanations include 1)
phosphorylation-mediated activation of Pit-1 protein; 2) cAMP
responsiveness through nonclassical cAMP response element motifs in the
hGH promoter; 3) CREB-independent regulation by CREB binding
protein; or 4) MAPK activation.
It has been demonstrated that GHRH induces c-Fos expression (23, 24), a factor that may be involved in the proliferation of
somatotrope cells. Somatostatin inhibits the proliferation of GH3
cells, and it inhibits GHRH induced c-fos expression (25).
The mitogenic effect of GHRH has been known to be mediated by the
activation of the cAMP pathway; increased cAMP stimulates c-Fos
expression through its cAMP response element. In GH3 cells, Pit-1
also enhances c-Fos promoter activity by binding to the serum response
element in the c-Fos promoter (26). In this study we
observed that GHRH stimulated the proliferation of GH3 cells
expressing GHRH receptor. We also demonstrated activation of MAPK and
an increase in c-Fos expression after treatment with GHRH. Recently,
Pombo et al. (27) demonstrated MAPK activation
by GHRH in CHO cells stably expressing GHRH receptor. It has been
demonstrated that cAMP analogs and TRH activate MAPK, leading to
cellular proliferation of GH3 cells (28, 29). MAPK is
instrumental in several signal transduction pathways involved in cell.
Once activated, MAPK translocates to the nucleus, where it induces
transcription factors, including c-Fos and c-Jun. It is likely that
MAPK activation plays a role in mediating the mitogenic action of
GHRH.
In summary, we demonstrated restoration of GHRH responsiveness of
pituitary GH3 cells in response to GHRH after expression of
functional hGHRH receptor using recombinant adenoviral vectors. These
results indicate that adenoviral vectors carrying the hGHRH receptor
gene are useful for in vitro studies of GHRH receptor
biology and represent a first step toward the long-term goal of gene
therapy for dwarfism caused by GHRH receptor mutations.
 |
Acknowledgments
|
|---|
We are grateful to Brigitte G. Mann for the measurement of GH
and PRL. We also thank Dr. Kelly E. Mayo for providing GHRH receptor
complementary DNA, Dr. Bruce Gaylinn for providing antibody for hGHRH
receptor, Dr. A. F. Parlow for providing the RIA kit for rat GH
and rat PRL, and Dr. Jeffrey Weiss for critical reading and helpful
discussion.
 |
Footnotes
|
|---|
1 This work was supported by a Center of Excellence grant from
Knoll Pharmaceutical Co. 
Received August 1, 2000.
 |
References
|
|---|
-
Billestrup N, Swanson LW, Vale W 1986 Growth
hormone-releasing factor stimulates proliferation of somatotrophs in
vitro. Proc Natl Acad Sci USA 83:68546857[Abstract/Free Full Text]
-
Mayo KE 1992 Molecular cloning and expression of a
pituitary specific receptor for growth hormone-releasing hormone. Mol
Endocrinol 6:17341744[Abstract]
-
Gaylinn BD, Harrison JK, Zysk JR, Lyon CE, Lynch KR,
Thorner MO 1993 Molecular cloning and expression of a human
anterior pituitary receptor for growth hormone-releasing hormone. Mol
Endocrinol 7:7784[Abstract]
-
Gaylinn BD 1999 Molecular and cell biology of the
growth hormone-releasing hormone receptor. Growth Hormone IGF Res 9:3744
-
Mayo KE, Miller TL, DeAlmeida VI, Zheng J,
Godfrey PA 1996 The growth hormone-releasing hormone receptor:
signal transduction, gene expression, and physiological function in
growth regulation. Ann NY Acad Sci 805:184203[Abstract]
-
Godfrey G, Rahal JO, Beamer WG, Copeland NG, Jenkins
NA, Mayo KE 1993 GHRH receptor of little mice contains a missense
mutation in the extracellular domain that disrupts receptor function.
Nat Genet 4:227232[CrossRef][Medline]
-
Gaylinn BD, Dealmeida VI, Lyons Jr CE, Wu KC, Mayo KE,
Thorner MO 1999 The mutant growth hormone-releasing hormone (GHRH)
receptor of the little mouse does not bind GHRH. Endocrinology 140:50665074[Abstract/Free Full Text]
-
Wajnrajch MP, Gertner JM, Harbison MD, Chua Jr SC,
Leibel RL 1996 Nonsense mutation in the human growth
hormone-releasing hormone receptor causes growth failure analogous to
the little (lit) mouse. Nat Genet 12:8890[CrossRef][Medline]
-
Netchine I, Talon P, Dastot F, Vitaux F, Goossens M,
Amselem S 1998 Extensive phenotypic analysis of a family with
growth hormone (GH) deficiency caused by a mutation in the GH-releasing
hormone receptor gene. J Clin Endocrinol Metab 83:432436[Abstract/Free Full Text]
-
Salvatori R, Hayashida CY, Aguiar-Oliveria MH, Phillips
III JA, Souza AHO, Gondo RG, Toledo SPA, Conceicao MM, Prince M,
Maheshwari HG, Baumann G, Levine MA 1999 Familial dwarfism due to
a novel mutation of the growth hormone releasing hormone receptor gene.
J Clin Endocrinol Metab 84:917923[Abstract/Free Full Text]
-
Perez FR, Casabiell X, Camina JP, Zugaza JL, Casanueva
FF 1997 cis-unsaturated free fatty acids block growth
hormone and prolactin secretion in thyrotropin-releasing
hormone-stimulated GH3 cells by perturbing the function of plasma
membrane integral proteins. Endocrinology 138:264272[Abstract/Free Full Text]
-
Zeytin FN, Gick GG, Brazeau P, Ling N, McLaughlin M,
Bancroft C 1984 Growth hormone (GH)-releasing factor does not
regulate GH release or GH mRNA levels in GH3 cells. Endocrinology 114:20542059[Abstract]
-
Lee EJ, Anderson LM, Thimmapaya B, Jameson JL 1999 Targeted expression of toxic genes directed by pituitary hormone
promoters: a potential strategy for adenoviral-mediated gene therapy of
pituitary tumors. J Clin Endocrinol Metab 84:786794[Abstract/Free Full Text]
-
Shapiro DJ, Sharp PA, Wahli WW, Keller MJ 1988 A
high efficiency HeLa cell nuclear transcription extract. DNA 7:4755[Medline]
-
Ali M, Lemonine N, Ring CJA 1994 The use of DNA
viruses as vectors for gene therapy. Gene Ther 1:367384[Medline]
-
Wivel MM, Gao GP, Wilson JM 1999 Adenoviral
vectors. In: Friedmann T (ed) The Development of Human Gene Therapy.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp 87110
-
Gaylinn BD, Lyon CE, Zysk JR, Clarke IJ, Thorner MO 1994 Photoaffinity cross-linking to the pituitary receptor for growth
hormone-releasing factor. Endocrinology 135:950955[Abstract]
-
Lussier BT, French MB, Moore BC, Kraicer J 1991 Free intracellular Ca2+ concentration
([Ca2+]i) and growth
hormone release from purified rat somatotrophs. I. GH-releasing
factor-induced Ca2+ influx raises
([Ca2+]i). Endocrinology 128:570582[Abstract]
-
Barinaga M, Yamonoto G, Rivier C, Vale W, Evan R,
Rosenfeld MG 1983 Transcriptional regulation of growth hormone
gene expression by growth hormone-releasing factor. Nature 306:8485[CrossRef][Medline]
-
Barinaga M, Bilezikjian LM, Vale W, Rosenfeld MG, Evan
R 1985 Independent effects of growth hormone releasing factor on
growth hormone release and gene transcription. Nature 314:279281[CrossRef][Medline]
-
Zhang K, Kulig E, Jin L, Lloyd RV 1993 Effects of
estrogen and epidermal growth factor on prolactin and Pit-1 mRNA in GH3
cells. Proc Soc Exp Biol Med 202:193200[Abstract]
-
Ying C, Lin DH, Sarkar DK, Chen TT 1999 Interaction
between estrogen receptor and Pit-1 protein is influenced by estrogen
in pituitary cells. J Steroid Biochem Mol Biol 68:145152[CrossRef][Medline]
-
Billestrup N, Mitchell RL, Vale W, Verma IM 1987 Growth hormone-releasing factor induces c-fos expression in cultured
primary pituitary cells. Mol Endocrinol 1:300305[Abstract]
-
Bertherat J 1997 Nuclear effects of the cAMP
pathway activation in somatotrophs. Horm Res 47:245250[Medline]
-
Pelicci G, Pagliacci MC, Lanfrancone L, Pelicci PG,
Grignani F, Nicoletti I 1990 Inhibitory effect of the somatostatin
analog octreotide on rat pituitary tumor cell (GH3) proliferation
in vitro. J Endocrinol Invest 13:657662[Medline]
-
Gaiddon C, Tapia Md, Loeffler JP 1999 The
tissue-specific transcription factor Pit-I/GHF-1 bind to the c-fos
serum element and activates c-fos transcription. Mol Endocrinol 13:742751[Abstract/Free Full Text]
-
Pombo CM, Zalvide J, Gaylinn BD, Dieguez C 2000 Growth hormone- releasing hormone stimulates mitogen-activated
protein kinase. Endocrinology 141:21132119[Abstract/Free Full Text]
-
Kanasaki H, Fukunaga K, Takahasi K, Miyazaki K, Miyamoto
E 1999 Mitogenic-activated protein kinase activation by
stimulation with thyrotropin-releasing hormone in art pituitary
GH3 cells. Biol Reprod 61:319325[Abstract/Free Full Text]
-
Suzuki S, Yamamoto I, Arita J 1999 Mitogenic-activated protein kinase- dependent stimulation of
proliferation of rat lactotrophs in culture by 3',5'-cyclic adenosine
monophosphate. Endocrinology 140:28502858[Abstract/Free Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
Z. Wang, T. Mitsui, M. Ishida, and J. Arita
Adenovirus vectors differentially modulate proliferation of pituitary lactotrophs in primary culture in a mitogen and infection time-dependent manner
J. Endocrinol.,
July 1, 2008;
198(1):
209 - 217.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F.-y. Gong, Y.-f. Shi, and J.-y. Deng
The regulatory mechanism by which interleukin-6 stimulates GH-gene expression in rat GH3 cells.
J. Endocrinol.,
August 1, 2006;
190(2):
397 - 406.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. J. Lee and J L. Jameson
Gene therapy of pituitary diseases
J. Endocrinol.,
June 1, 2005;
185(3):
353 - 362.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Jirawatnotai, A. Aziyu, E. C. Osmundson, D. S. Moons, X. Zou, R. D. Kineman, and H. Kiyokawa
Cdk4 Is Indispensable for Postnatal Proliferation of the Anterior Pituitary
J. Biol. Chem.,
December 3, 2004;
279(49):
51100 - 51106.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. S. Kostic, S. A. Andric, and S. S. Stojilkovic
Receptor-Controlled Phosphorylation of {alpha}1 Soluble Guanylyl Cyclase Enhances Nitric Oxide-Dependent Cyclic Guanosine 5'-Monophosphate Production in Pituitary Cells
Mol. Endocrinol.,
February 1, 2004;
18(2):
458 - 470.
[Abstract]
[Full Text]
[PDF]
|
 |
|